Piperazine derivatives
    1.
    发明授权
    Piperazine derivatives 失效
    哌嗪衍生物

    公开(公告)号:US5369103A

    公开(公告)日:1994-11-29

    申请号:US861834

    申请日:1992-06-19

    CPC分类号: C07D295/185 C07D213/56

    摘要: ##STR1## where A is an alkylene chain of 1 or 2 carbon atoms optionally substituted by one or more lower alkyl groups, R is hydrogen or lower alkyl, R
    1 is a mono or bicyclic aryl or a heteroaryl radical, R
    2 is an aryl radical, a heteroaryl radical, or an aryl-or heteroaryl-lower alkyl radical, R
    3 is hydrogen, lower alkyl or aryl and R
    4 is hydrogen, lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, or aryl(lower)alkyl or R
    3 and R
    4 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom and the dotted line represents a single or double bond, the hydrogen atoms shown in brackets being present when the dotted line represents a single bond and their pharmaceutically acceptable acid addition salts are 5-HT
    1A binding agents which may be used, for example, for the treatment of CNS disorders such as anxiety.

    摘要翻译: (I)其中A是任选被一个或多个低级烷基取代的1或2个碳原子的亚烷基链,R是氢或低级烷基,R 1是单或双环芳基或杂芳基,R 2是 芳基,芳基或杂芳基 - 低级烷基,R3是氢,低级烷基或芳基,R4是氢,低级烷基,环烷基,环烷基(低级)烷基,芳基或芳基(低级)烷基 或者R 3和R 4与它们所连接的氮原子一起表示饱和杂环,其可以含有另外的杂原子,虚线表示单键或双键,当虚线表示时,括号中所示的氢原子存在 代表单键,并且其药学上可接受的酸加成盐是可用于例如治疗CNS病症如焦虑症的5-HT1A结合剂。

    N-(2,3-dihydro-1,4-benzodioxinyl)-N-substituted aminopyrido-fused
cycloalkanes
    2.
    发明授权
    N-(2,3-dihydro-1,4-benzodioxinyl)-N-substituted aminopyrido-fused cycloalkanes 失效
    N-(2,3-二氢-1,4-苯并二恶英基)-N-取代的氨基吡啶并 - 稠合的环烷烃

    公开(公告)号:US5194439A

    公开(公告)日:1993-03-16

    申请号:US765282

    申请日:1991-09-25

    IPC分类号: C07D215/38 C07D405/12

    CPC分类号: C07D405/12 C07D215/38

    摘要: Pyridine derivatives of formula ##STR1## their heteroaromatic N-oxides and their pharmaceutically acceptable acid addition salts are disclosed. In the formula z is 0, 1 and 2; R is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, trifluoromethyl, nitro, amino, (lower)alkylamino or di(lower)alkylamino; R.sup.1 is hydrogen or lower alkyl; R.sup.2 is --(CH.sub.2).sub.n --R.sup.3 or --CH.sub.2 --CH.dbd.CH--(CH.sub.2).sub.m --R.sup.3 or --CH.sub.2.C.tbd.C.(CH.sub.2).sub.m --R.sup.3 where n is 1 to 6, and m is 0 to 3; and R.sup.3 is a ring of formula ##STR2## The compounds exhibit activity as 5-HT.sub.1A agonists, antagonists or partial agonists and are used for the treatment of CNS disorders, e.g. anxiety, as antihypertensives and in treating anorexia.

    摘要翻译: 公开了式(I)的吡啶衍生物,它们的杂芳族N-氧化物及其药学上可接受的酸加成盐。 式中Z为0,1和2; R为氢,羟基,低级烷基,低级烷氧基,卤素,三氟甲基,硝基,氨基,(低级)烷基氨基或二(低级)烷基氨基; R1是氢或低级烷基; R 2是 - (CH 2)n -R 3或-CH 2 -CH = CH-(CH 2)m -R 3或-CH 2 C 3 OCH 3(CH 2)m -R 3,其中n为1至6,m为0至3 ; 并且R 3是式的环。化合物表现出作为5-HT 1A激动剂,拮抗剂或部分激动剂的活性,并且用于治疗CNS疾病,例如, 焦虑,作为抗高血压药物和治疗厌食症。

    Pyrimidoindoles useful as hypoglycaemics
    3.
    发明授权
    Pyrimidoindoles useful as hypoglycaemics 失效
    嘧啶二醇可用作低血糖症

    公开(公告)号:US4784996A

    公开(公告)日:1988-11-15

    申请号:US23337

    申请日:1987-03-09

    IPC分类号: C07D487/04 A61K31/505

    CPC分类号: C07D487/04

    摘要: Compounds of formula ##STR1## wherein A represents a lower alkylene chain optionally containing one double or triple bond, RO represents (lower)alkoxy, aryl(lower)alkoxy, hydroxy or protected hydroxy, R.sup.1 and R.sup.2 which may be the same or different each represent hydrogen, hydroxyl, lower alkyl, lower alkoxy, halo(lower)alkyl, halogen, amino or mono- or di(lower)alkylamino and R.sup.3 and R.sup.4 each independently represent hydrogen or lower alkyl and their pharmaceutically acceptable acid addition salts are useful as hypoglycaemics or as intermediates for hypoglycaemics.

    摘要翻译: 式(I)的化合物其中A表示任选含有一个双键或三键的低级亚烷基链,RO表示(低级)烷氧基,芳基(低级)烷氧基,羟基或被保护的羟基,R 1和R 2可以相同 或各自代表氢,羟基,低级烷基,低级烷氧基,卤代(低级)烷基,卤素,氨基或单或二(低级)烷基氨基,并且R 3和R 4各自独立地表示氢或低级烷基及其药学上可接受的酸加成盐 作为低血糖症或低血糖症的中间体是有用的。

    Amide derivatives
    5.
    发明授权
    Amide derivatives 失效
    酰胺衍生物

    公开(公告)号:US5585374A

    公开(公告)日:1996-12-17

    申请号:US379579

    申请日:1995-02-01

    CPC分类号: C07D401/04 C07D211/70

    摘要: Amide derivatives of formula (I) and their pharmaceutically acceptable salts (where a and b each represent 0, 1, 2 or 3 such that a+b=0, 1, 2 or 3, the dotted line represents an optional double bond, A is an optionally substituted C.sub.1-2 -alkylene chain, R is mono or bicyclic aryl or heteroaryl radical, R.sup.1 is hydrogen or lower alkyl, R.sup.2 is an aryl, aralkyl, heteroaryl or heteroarylalkyl and --CONR.sup.3 R.sup.4 represents a specified amide group) are 5-HT.sub.1A binding agents and may be used, for example, as anxiolytics. ##STR1##

    摘要翻译: PCT No.PCT / GB93 / 01542 Sec。 371日期:1995年2月1日 102(e)1995年2月1日PCT PCT 1993年7月22日PCT公布。 第WO94 / 03444号公报 日期1994年2月12日制备式(I)衍生物及其药学上可接受的盐(其中a和b各自表示0,1,2或3,使得a + b = 0,1,2或3,虚线表示 A为任选取代的C 1-2 - 亚烷基链,R为单或双环芳基或杂芳基,R 1为氢或低级烷基,R 2为芳基,芳烷基,杂芳基或杂芳基烷基,且-CONR 3 R 4为特定的酰胺基 组)是5-HT1A结合剂,可以用作例如抗焦虑剂。 (一)

    Azetidine derivatives and hypotensive compositions thereof
    8.
    发明授权
    Azetidine derivatives and hypotensive compositions thereof 失效
    AZETIDINE衍生物及其高分子组合物

    公开(公告)号:US5164385A

    公开(公告)日:1992-11-17

    申请号:US756410

    申请日:1991-09-09

    IPC分类号: C07D205/04

    CPC分类号: C07D205/04

    摘要: Azetidine derivatives of formula ##STR1## and their pharmaceutically acceptable acid addition salts are disclosed. In the formula R is hydrogen or one or more specified substituents. The compounds have hypotensive activity. Some are also 5-HT.sub.1A agonists.

    摘要翻译: 公开了式(I)的氮杂环丁烷衍生物及其药学上可接受的酸加成盐。 式中R是氢或一个或多个特定的取代基。 这些化合物具有降血压活性。 有些也是5-HT1A激动剂。

    Anti-obesity agents
    10.
    发明授权
    Anti-obesity agents 失效
    抗肥胖剂

    公开(公告)号:US4451465A

    公开(公告)日:1984-05-29

    申请号:US391071

    申请日:1982-06-22

    摘要: 2,3,4,10-Tetrahydro-3,3-dimethyl-10-phenylpyrimido[1,2-a]indol-10-ol and the pharmaceutically acceptable acid addition salts thereof are useful in treatment or preventing obesity in mammals. The compounds may be administered in pharmaceutical compositions, optionally with one or more vitamins.

    摘要翻译: 2,3,4,10-四氢-3,3-二甲基-10-苯基嘧啶并[1,2-a]吲哚-10-醇及其药学上可接受的酸加成盐可用于治疗或预防哺乳动物的肥胖。 化合物可以以药物组合物,任选地与一种或多种维生素一起施用。